crisaborole (Eucrisa)
Jump to navigation
Jump to search
Introduction
FDA-approval Dec 2016
Indications
* complete or near complete clearance in 1/3 of patients within 1 month[2]
Dosage
- ointment applied topically twice daily
Adverse effects
- pain, burning, stinging at sit of application
- hypersensitivity reactions
Mechanism of action
Notes
- manufactured by Palo Alto, California-based Anacor Pharmaceuticals, Inc.
More general terms
References
- ↑ Brown T FDA Approves Crisaborole (Eucrisa) for Atopic Dermatitis. Medscape. Dec 14, 2016. http://www.medscape.com/viewarticle/873305
FDA News Release. December 14, 2016 FDA approves Eucrisa for eczema. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm533371.htm - ↑ 2.0 2.1 Bankhead C MedPageToday. March 7, 2017 American Academy of Dermatology (AAD) Meeting Coverage. Studies Confirm Efficacy of Topical PDE4 Inhibitor - Significant improvement in atopic dermatitis within a week https://www.medpagetoday.com/MeetingCoverage/AAD/63654
Fowler JF, et al. Crisaborole ointment improves global atopic dermatitis severity: Pooled results from two phase III clinical trials. American Academy of Dermatology (AAD 2017). Abstract 5667.